Owen Hughes - Net Worth and Insider Trading

Owen Hughes Net Worth

The estimated net worth of Owen Hughes is at least $8 Million dollars as of 2024-11-05. Owen Hughes is the President and CEO of Cullinan Therapeutics Inc and owns about 506,226 shares of Cullinan Therapeutics Inc (CGEM) stock worth over $8 Million. Owen Hughes is the Director of Radius Health Inc and owns about 10,650 shares of Radius Health Inc (RDUS) stock worth over $345,806. Owen Hughes is also the Exec Chairman and Interim CEO of XOMA Royalty Corp and owns about 2,000 shares of XOMA Royalty Corp (XOMA) stock worth over $60,440. Besides these, Owen Hughes also holds Translate Bio Inc (TBIO) . Details can be seen in Owen Hughes's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Owen Hughes has not made any transactions after 2023-10-02 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Owen Hughes

Owen Hughes Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Owen Hughes owns 7 companies in total, including Translate Bio Inc (TBIO) , Radius Health Inc (RDUS) , and Cullinan Therapeutics Inc (CGEM) among others .

Click here to see the complete history of Owen Hughes’s form 4 insider trades.

Insider Ownership Summary of Owen Hughes

Ticker	Comapny	Transaction Date	Type of Owner
TBIO	Translate Bio Inc	2021-09-14	director
RDUS	Radius Health Inc	2022-08-15	director
CGEM	Cullinan Therapeutics Inc	2021-01-12	director & President and CEO
		2021-02-16	director
		2023-01-03	director & Interim CEO
		2022-12-14	director
		2023-10-02	director & Interim CEO

Owen Hughes Latest Holdings Summary

Owen Hughes currently owns a total of 4 stocks. Among these stocks, Owen Hughes owns 506,226 shares of Cullinan Therapeutics Inc (CGEM) as of January 12, 2021, with a value of $8 Million and a weighting of 95.15%. Owen Hughes owns 10,650 shares of Radius Health Inc (RDUS) as of February 26, 2020, with a value of $345,806 and a weighting of 4.13%. Owen Hughes also owns 2,000 shares of XOMA Royalty Corp (XOMA) as of October 2, 2023, with a value of $60,440 and a weighting of 0.72%. The other 1 stocks Translate Bio Inc (TBIO) have a combined weighting of 0% among all his current holdings.

Latest Holdings of Owen Hughes

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
CGEM	Cullinan Therapeutics Inc	2021-01-12	506,226	15.73	7,962,935
RDUS	Radius Health Inc	2020-02-26	10,650	32.47	345,806
XOMA	XOMA Royalty Corp	2023-10-02	2,000	30.22	60,440
TBIO	Translate Bio Inc	2021-09-14	0	37.36	0

Holding Weightings of Owen Hughes

Owen Hughes Form 4 Trading Tracker

According to the SEC Form 4 filings, Owen Hughes has made a total of 1 transactions in Cullinan Therapeutics Inc (CGEM) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Cullinan Therapeutics Inc is the acquisition of 2,500 shares on January 12, 2021, which cost Owen Hughes around $52,500.

According to the SEC Form 4 filings, Owen Hughes has made a total of 1 transactions in Radius Health Inc (RDUS) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Radius Health Inc is the sale of 2,750 shares on February 26, 2020, which brought Owen Hughes around $49,363.

According to the SEC Form 4 filings, Owen Hughes has made a total of 3 transactions in XOMA Royalty Corp (XOMA) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in XOMA Royalty Corp is the acquisition of 1,000 shares on October 2, 2023, which cost Owen Hughes around $13,830.

More details on Owen Hughes's insider transactions can be found in the Insider Trading History of Owen Hughes table.

Insider Trading History of Owen Hughes

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Owen Hughes Trading Performance

GuruFocus tracks the stock performance after each of Owen Hughes's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Owen Hughes is 16.33%. GuruFocus also compares Owen Hughes's trading performance to market benchmark return within the same time period. The performance of stocks bought by Owen Hughes within 3 months outperforms 2 times out of 4 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Owen Hughes's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Owen Hughes

Average Return

Average return per transaction

Outperforming Transactions

3 out of 4 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	24.16
Relative Return to S&P 500(%)	22.49

Owen Hughes Ownership Network

Ownership Network List of Owen Hughes

No Data

Ownership Network Relation of Owen Hughes

Owen Hughes Owned Company Details

What does Translate Bio Inc do?

Who are the key executives at Translate Bio Inc?

Owen Hughes is the director of Translate Bio Inc. Other key executives at Translate Bio Inc include director & Chief Executive Officer & other: President Renaud Ronald C Jr , Chief Operating Officer & CLO & other: Secretary Paul D. Burgess , and 10 percent owner Shire Human Genetic Therapies, Inc. .

Translate Bio Inc (TBIO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Translate Bio Inc (TBIO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Translate Bio Inc (TBIO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Translate Bio Inc (TBIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Translate Bio Inc Insider Transactions

No Available Data

What does Radius Health Inc do?

Who are the key executives at Radius Health Inc?

Owen Hughes is the director of Radius Health Inc. Other key executives at Radius Health Inc include director & CEO and President G. Kelly Martin , Senior Vice President Elizabeth Messersmith , and Vice President & Sales Danielle Holtschlag .

Radius Health Inc (RDUS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Radius Health Inc (RDUS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Radius Health Inc (RDUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Radius Health Inc (RDUS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Radius Health Inc Insider Transactions

No Available Data

What does Cullinan Therapeutics Inc do?

Who are the key executives at Cullinan Therapeutics Inc?

Owen Hughes is the director & President and CEO of Cullinan Therapeutics Inc. Other key executives at Cullinan Therapeutics Inc include See Remarks Jennifer Michaelson , Acting Chief Business Officer Savill Corrine , and director & President and CEO Nadim Ahmed .

Cullinan Therapeutics Inc (CGEM) Insider Trades Summary

Over the past 18 months, Owen Hughes made no insider transaction in Cullinan Therapeutics Inc (CGEM). Other recent insider transactions involving Cullinan Therapeutics Inc (CGEM) include a net sale of 94,903 shares made by Jennifer Michaelson , a net sale of 5,708 shares made by Jeffrey Trigilio , and a net sale of 3,027 shares made by Jeffrey Alan Jones .

In summary, during the past 3 months, insiders sold 8,000 shares of Cullinan Therapeutics Inc (CGEM) in total and bought 0 shares, with a net sale of 8,000 shares. During the past 18 months, 231,648 shares of Cullinan Therapeutics Inc (CGEM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 231,648 shares.

Cullinan Therapeutics Inc (CGEM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cullinan Therapeutics Inc Insider Transactions

No Available Data

What does Pardes Biosciences Inc do?

Who are the key executives at Pardes Biosciences Inc?

Owen Hughes is the director of Pardes Biosciences Inc. Other key executives at Pardes Biosciences Inc include 10 percent owner Fs Development Holdings Ii, Llc , 10 percent owner Foresite Capital Fund V, L.p. , and 10 percent owner Foresite Capital Opportunity Fund V, L.p. .

Pardes Biosciences Inc (PRDS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Pardes Biosciences Inc (PRDS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Pardes Biosciences Inc (PRDS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Pardes Biosciences Inc (PRDS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Pardes Biosciences Inc Insider Transactions

No Available Data

What does XOMA Royalty Corp do?

Who are the key executives at XOMA Royalty Corp?

Owen Hughes is the director & Interim CEO of XOMA Royalty Corp. Other key executives at XOMA Royalty Corp include Chief Investment Officer Bradley Sitko , 10 percent owner Bvf I Gp Llc , and 10 percent owner Bvf Gp Holdings Llc .

XOMA Royalty Corp (XOMAO.PFD) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of XOMA Royalty Corp (XOMAO.PFD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of XOMA Royalty Corp (XOMAO.PFD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

XOMA Royalty Corp (XOMAO.PFD)'s detailed insider trading history can be found in Insider Trading Tracker table.

XOMA Royalty Corp Insider Transactions

No Available Data

What does Ikena Oncology Inc do?

Who are the key executives at Ikena Oncology Inc?

Owen Hughes is the director of Ikena Oncology Inc. Other key executives at Ikena Oncology Inc include CFO & Head of Corp. Dev. Jotin Marango , Principal Accounting Officer Francisco Oliveira , and Chief Scientific Officer Xiaoyan Michelle Zhang .

Ikena Oncology Inc (IKNA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Ikena Oncology Inc (IKNA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Ikena Oncology Inc (IKNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Ikena Oncology Inc (IKNA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ikena Oncology Inc Insider Transactions

No Available Data

What does XOMA Royalty Corp do?

Who are the key executives at XOMA Royalty Corp?

Owen Hughes is the director & Interim CEO of XOMA Royalty Corp. Other key executives at XOMA Royalty Corp include Chief Investment Officer Bradley Sitko , other: See Explanation of Responses Biotechnology Value Fund L P , and Chief Financial Officer Thomas M. Burns .

XOMA Royalty Corp (XOMA) Insider Trades Summary

Over the past 18 months, Owen Hughes made 3 insider transaction in XOMA Royalty Corp (XOMA) with a net purchase of 5,500. Other recent insider transactions involving XOMA Royalty Corp (XOMA) include a net purchase of 9,100 shares made by Bradley Sitko ,

In summary, during the past 3 months, insiders sold 0 shares of XOMA Royalty Corp (XOMA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of XOMA Royalty Corp (XOMA) were sold and 14,600 shares were bought by its insiders, resulting in a net purchase of 14,600 shares.

XOMA Royalty Corp (XOMA)'s detailed insider trading history can be found in Insider Trading Tracker table.

XOMA Royalty Corp Insider Transactions

No Available Data

Owen Hughes Mailing Address

Above is the net worth, insider trading, and ownership report for Owen Hughes. You might contact Owen Hughes via mailing address: C/o Radius Health, Inc., 201 Broadway, 6th Floor, Boston Ma 02139.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.